Aussie icon Sophie Monk calls on Australians to get behind Melanoma March
26 February 2019
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Sophie today toured Melanoma Institute Australia’s research and treatment centre in Sydney, where she met a young family devastated by melanoma. She spent time with little Madi who was only three-years-old when she lost her dad Peter to melanoma.
MIA CEO Matthew Browne says the organisation is thrilled to have Sophie onboard as the Queensland-based media personality is relatable to 15-39 year olds, the age bracket in which melanoma is the most common cancer.
"Sophie, like many Australians, has grown up living an outdoor, active lifestyle which all too often can have dire consequences,” Matthew said. “Many people don’t realise how common melanoma is, with more than 14,000 Australians expected to be diagnosed with the disease this year. By having Sophie onboard we will better be able to reach young Australians with sun-safety and skin awareness messages."
After having a close friend diagnosed with melanoma, and then watching her dad battle with skin cancer, Sophie was shocked to learn that melanoma is the most common cancer affecting 15 to 39 year old Australians.
I love going to the beach as much as the next Australian, but now seeing just how prevalent melanoma is among young people, it has prompted me to spread the sun safety message so no one has to go through this devastating diagnosis, Sophie said.
Sophie will use her public profile as one of Australia’s most loved television and radio personalities to warn other young Aussies of the risk of sun exposure and the need to be vigilant in checking their skin for changes.
"When I first came back to Australia the thing I noticed most was how much time Australians spend in the sun, so I was constantly reminding my family to put on sunscreen. We should all be using sunscreen and checking our skin, in the same way we clean our teeth every day. And if you notice any changes to your skin, you need to get checked professionally ASAP. I know it can be a pain but it could be the difference between life and death. I’ll be nagging all my friends and family to book in to get their initial skin check!"
Sophie has also generously come on board as an Ambassador for Melanoma Institute Australia’s national awareness campaign, Melanoma March, which includes 23 family friendly walks across every state and territory in Australia, as well as the 2000km Jay’s Longest Melanoma March from Adelaide to Sydney. The campaign raises vital funds for melanoma research.
Our goal is zero deaths from melanoma, and whilst recent clinical advances have tripled life expectancy of some advanced melanoma patients, we still have one Australian dying from the disease every five hours,” said Matthew Browne. “It is vital we fund ongoing research so we can save more lives.
"I grew up in sunny Queensland and it’s only through hearing the devastating stories about melanoma that I now realise how deadly the disease can be, and the importance of sun safety, especially among the younger generation,” Sophie said.
Join your local Melanoma March to help raise awareness as well as much-needed funds so that one day no one will have to die from melanoma,” Sophie said.
For more information on how to register for a march near you or donate to Melanoma March, go to www.melanomamarch.org.au
Melanoma March 2019 is an initiative of Melanoma Institute Australia. In South Australia, we work alongside Australian Melanoma Research Foundation; in Western Australia, we work with melanomaWA; and in Victoria, we work with the Skin & Cancer Foundation Inc.
Melanoma March 2019 Principal Partner is Ricky, and Supporting Partners include Sun Sense, Skin & Cancer Foundation Inc., Toyota and Kensington Parry.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.